Complexing agent salt formulations of pharmaceutical compounds

A pharmaceutical composition comprising a pharmaceutically acceptable salt of a pharmaceutical compound, comprising:

• (i) the pharmaceutical compound, or an enantiomer, a mixture of enantiomers, or an isotopic variant thereof;
• or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein the pharmaceutical compound comprises a protonated nitrogen atom, wherein the pharmaceutical compound is not ketamine;
• and
• (ii) a conjugate base of a complexing agent comprising a plurality of acidic functional groups, wherein the conjugate base of the complexing agent acts as the counterion of the pharmaceutical compound, wherein the complexing agent is substituted cyclodextrin;
• wherein the pharmaceutical composition is formulated for subcutaneous or intramuscular administration as an aqueous formulation having a pH of at least about 5.5;
• wherein the osmolality of the pharmaceutical composition is lower than an osmolality of a composition comprising an equivalent amount of a freebase form of the pharmaceutical compound encapsulated within a hydrophobic core of a salt of the complexing agent;
• wherein the composition has a molar ratio of the pharmaceutical compound to the complexing agent of at least 1:1.

An pharmaceutical composition comprising a pharmaceutically acceptable salt of a pharmaceutical compound having the formula:

• [A]a[B]
• wherein:
• A is a pharmaceutical compound comprising at least one basic nitrogen atom, wherein the pharmaceutical compound is not ketamine;
• B is a complexing agent comprising a plurality of acidic functional groups;
• and
• a is a number from 1-7, wherein the number is selected such that the total number of basic nitrogen atoms of A is equal to the number of acidic functional groups of B,
• wherein the complexing agent is cyclodextrin;
• wherein the pharmaceutical composition is formulated for subcutaneous or intramuscular administration as an aqueous formulation having a pH of at least about 5.5;
• wherein the osmolality of the pharmaceutical composition is lower than an osmolality of a composition comprising an equivalent amount of a freebase form of the pharmaceutical compound encapsulated within a hydrophobic core of a salt of the complexing agent;
• wherein the composition has a molar ratio of the pharmaceutical compound to the complexing agent of at least 1:1.